All questionsPharmacology: Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) in HIV-1 infection5 questions · 1 sourceComponentsWhat is in Biktarvy?“BIKTARVY is a three-drug fixed dose combination product containing bictegravir (BIC), emtricitabine (FTC), and tenofovir alafenamide (TAF).” (opens the source at this quote in a new tab)CopyFlag“BIC is an integrase strand transfer inhibitor (INSTI). • FTC, a synthetic nucleoside analog of cytidine, is an HIV nucleoside analog reverse transcriptase inhibitor (HIV NRTI). • TAF, an HIV NRTI, is converted in vivo to tenofovir, an acyclic nucleoside phosphonate (nucleotide) analog of adenosine 5′-monophosphate.” (opens the source at this quote in a new tab)CopyFlag“BIKTARVY tablets are available in two dose strengths: • 50 mg/200 mg/25 mg tablets: 50 mg of bictegravir (BIC) (equivalent to 52.5 mg of bictegravir sodium), 200 mg of emtricitabine (FTC), and 25 mg of tenofovir alafenamide (TAF) (equivalent to 28 mg of tenofovir alafenamide fumarate). These tablets are purplish brown, capsule-shaped, film-coated, and debossed with “GSI” on one side and “9883” on the other side. • 30 mg/120 mg/15 mg tablets: 30 mg of BIC (equivalent to 31.5 mg of bictegravir sodium), 120 mg of FTC, and 15 mg of TAF (equivalent to 16.8 mg of tenofovir alafenamide fumarate). These tablets are pink, capsule-shaped, film-coated, and either debossed with “GSI” on one side and “B” on the other side; or with a non- functional bisecting score line on one side and “BVY” on the other side.” (opens the source at this quote in a new tab)CopyFlagWhat are the inactive ingredients in Biktarvy?“Both dose strengths of BIKTARVY tablets include the following inactive ingredients: croscarmellose sodium, magnesium stearate, and microcrystalline cellulose. The tablets for both dose strengths are film-coated with a coating material containing iron oxide black, iron oxide red, polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide.” (opens the source at this quote in a new tab)CopyFlagMechanismHow does Biktarvy work (mechanism of action)?“Bictegravir: BIC inhibits the strand transfer activity of HIV-1 integrase (integrase strand transfer inhibitor; INSTI), an HIV-1 encoded enzyme that is required for viral replication. Inhibition of integrase prevents the integration of linear HIV-1 DNA into host genomic DNA, blocking the formation of the HIV-1 provirus and propagation of the virus. Emtricitabine: FTC, a synthetic nucleoside analog of cytidine, is phosphorylated by cellular enzymes to form emtricitabine 5'-triphosphate. Emtricitabine 5'-triphosphate inhibits the activity of the HIV-1 RT by competing with the natural substrate deoxycytidine 5'-triphosphate and by being incorporated into nascent viral DNA which results in chain termination. Emtricitabine 5′-triphosphate is a weak inhibitor of mammalian DNA polymerases α, β, Ɛ, and mitochondrial DNA polymerase γ.” (opens the source at this quote in a new tab)CopyFlag“Tenofovir Alafenamide: TAF is a phosphonamidate prodrug of tenofovir (2′-deoxyadenosine monophosphate analog). Plasma exposure to TAF allows for permeation into cells and then TAF is intracellularly converted to tenofovir through hydrolysis by cathepsin A. Tenofovir is subsequently phosphorylated by cellular kinases to the active metabolite tenofovir diphosphate. Tenofovir diphosphate inhibits HIV-1 replication through incorporation into viral DNA by the HIV RT, which results in DNA chain-termination. Tenofovir diphosphate is a weak inhibitor of mammalian DNA polymerases that include mitochondrial DNA polymerase γ and there is no evidence of toxicity to mitochondria in cell culture.” (opens the source at this quote in a new tab)CopyFlagPharmacokineticsHow is Biktarvy metabolized and eliminated?“Pharmacokinetic Properties of the Components of BIKTARVY Bictegravir (BIC) Emtricitabine (FTC) Tenofovir Alafenamide (TAF)” (opens the source at this quote in a new tab)CopyFlag“Metabolic pathway(s) CYP3A UGT1A1 Not significantly metabolized Cathepsin Ad (PBMCs) CES1 (hepatocytes) Excretion Major route of elimination Metabolism Glomerular filtration and active tubular secretion Metabolism % of dose excreted in urinee 35 70 <1 % of dose excreted in fecese 60.3 13.7 31.7” (opens the source at this quote in a new tab)CopyFlag“PBMCs=peripheral blood mononuclear cells; CES1=carboxylesterase 1” (opens the source at this quote in a new tab)CopyFlag“In vivo, TAF is hydrolyzed within cells to form tenofovir (major metabolite), which is phosphorylated to the active metabolite, tenofovir diphosphate. In vitro studies have shown that TAF is metabolized to tenofovir by cathepsin A in PBMCs and macrophages; and by CES1 in hepatocytes.” (opens the source at this quote in a new tab)CopyFlag“e. Dosing in mass balance studies: single dose administration of [14C] BIC; single dose administration of [14C] FTC after multiple dosing of FTC for ten days; single dose administration of [14C] TAF.” (opens the source at this quote in a new tab)CopyFlagNote: Each row of Table 4 lists values in header order: bictegravir (BIC), emtricitabine (FTC), then tenofovir alafenamide (TAF).What is the half-life of Biktarvy?“Pharmacokinetic Properties of the Components of BIKTARVY Bictegravir (BIC) Emtricitabine (FTC) Tenofovir Alafenamide (TAF)” (opens the source at this quote in a new tab)CopyFlag“t1/2 (h)c 17.3 (14.8, 20.7) 10.4 (9.0, 12.0) 0.51 (0.45, 0.62)c” (opens the source at this quote in a new tab)CopyFlag“c. t1/2 values refer to median (Q1, Q3) terminal plasma half-life. Note that the active metabolite of TAF, tenofovir diphosphate, has a half-life of 150-180 hours within PBMCs.” (opens the source at this quote in a new tab)CopyFlagNote: Each row of Table 4 lists values in header order: bictegravir (BIC), emtricitabine (FTC), then tenofovir alafenamide (TAF).